



Innovation for Cellular Therapies

Vycellix™, Inc. is a closely-held biopharmaceutical company advancing innovative, immune-modulating small molecules designed to enhance innate and adaptive cellular therapies, facilitate cell therapy manufacturing processes and optimize human immune response against disease with a focus on cancers.

Visit us on the web at:
www.Vycellix.com

Our pipeline significantly impacts next-generation immune cell based therapies, redefining the manufacturing paradigm to maximize cost and speed efficiencies, as well as amplifying T cells and NK cells into more potent disease-targeting lymphocytes, which we have branded as Amplicytes™.



Molecule	Use	Product Description	Status
VY-OZ Gene Transduction Enhancer	EX VIVO	Reagent enables increased cell transduction for viral vector based manufacturing of gene-modified cytotoxic lymphocytes	Seeking GMP “Qualified Reagent” Status
	EX VIVO	Reagent enables increased gene editing rates for CRISPR/Cas9 systems	Seeking GMP “Qualified Reagent” Status
	IN VIVO	Therapeutic Targeting Inflammatory Diseases	Pre-clinical
	IN VIVO	Reagent enables the efficient delivery of oncolytic viral vectors to tumors	Pre-clinical
VY-X Cytotoxic Cell Enhancer	EX VIVO	Reagent transforms cytotoxic lymphocytes into Amplicytes™ with enhanced serial tumor killing capacity	Seeking GMP “Qualified Reagent” Status
	IN VIVO	Therapeutic reprograms endogenous lymphocytes into Amplicytes™ with enhanced serial tumor killing capacity	Pre-clinical

Vycellix’s pipeline reflects potential near-term commercial revenues for the ex vivo uses of VY-OZ and VY-X, as they will be deployed as GMP qualified manufacturing reagents in the production of cell therapy products.

Vycellix’s pipeline in vivo uses target cancers and inflammatory diseases, representing significant market opportunities.

What are Amplicytes?



When cytotoxic lymphocytes engage with Vycellix’s first-in-class, patent protected VY-X molecule, those immune cells undergo fundamental changes exhibited by the significant upregulation of potent disease-killing proteins (perforin and granzyme B).

Such enhanced T cells and NK cells are defined as proprietary cell products called Amplicytes™.



Near-Term Revenue Opportunity Represented by Reagent Pipeline:

Ex Vivo Platform:
Redefining the Manufacturing Paradigm for Adoptive Cell Transfer



Improves Gene Modification Efficiencies & Amplifies Cytotoxicity for CAR-T, TIL, TCR & NK

Collaborations: Vycellix has entered into collaborative agreements with leading academic and commercial entities with the shared mission to develop next-generation immunotherapies.

- **Moffitt Cancer Center**
an NCI Comprehensive Cancer Center
- **University of California at San Francisco**
Parker Institute for Cancer Immunotherapy
- **Boston Children's Hospital**
Harvard University
- **Affimed**
- **Bellicum Pharmaceuticals**

Corporate Highlights:

- Advancing a novel immune-modulating pipeline that regulates intracellular antiviral pathways to enhance innate & adaptive cancer immunotherapies.
- Commercializing a small molecule that optimizes the potential of targeted cancer therapies that utilize genetically-modified cytotoxic lymphocytes by significantly improving manufacturing efficiencies.
- Developing a first-in-class RNA modulator that spawns highly potent immune cells (Amplicytes™) with amplified serial cancer killing capability.
- Founded by leading scientists from Sweden's world-renowned Karolinska Institutet (KI), globally recognized for its Nobel Assembly, which annually awards the Nobel Prize in Physiology or Medicine.

Founding Leadership:



Evren Alici, M.D., Ph.D.: CEO & Chairman of the Board

Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Hans-Gustaf Ljunggren, M.D., Ph.D.: Chief Medical Officer

Former Dean of Research, Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



Douglas W. Calder: President

Strategic Advisor to the NSU Cell Therapy Institute; former Executive VP & Officer roles at the Vaccine & Gene Therapy Institute (VGTI), Accentia Biopharmaceuticals, Viragen and Biovest International



Samuel Duffey, Esq.: Exec VP, General Counsel

CEO & General Counsel of ViraCell, a cellular bioprocessing company; former roles include CEO, President & General Counsel of Biovest International, a public cancer vaccine company, and senior attorney at SEC



Michael J. Keller, J.D.: Exec VP, Intellectual Property

CEO, Keller Life Science Law; former roles include Chief Patent Counsel for IVAX, partner at leading IP law firms, and technology transfer roles at the National Cancer Institute (NCI)

For more information contact:

Douglas W. Calder: President
Phone: 772-418-6302
dcalder@Vycellix.com
www.Vycellix.com

